CN103429581B - 多环类衍生物、其制备方法及其在医药上的应用 - Google Patents

多环类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN103429581B
CN103429581B CN201280011690.XA CN201280011690A CN103429581B CN 103429581 B CN103429581 B CN 103429581B CN 201280011690 A CN201280011690 A CN 201280011690A CN 103429581 B CN103429581 B CN 103429581B
Authority
CN
China
Prior art keywords
alkyl
compound
dihydrobenzofuran
yloxy
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280011690.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103429581A (zh
Inventor
杨方龙
董庆
韩吉慧
王春飞
张羚
王阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201280011690.XA priority Critical patent/CN103429581B/zh
Publication of CN103429581A publication Critical patent/CN103429581A/zh
Application granted granted Critical
Publication of CN103429581B publication Critical patent/CN103429581B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280011690.XA 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用 Active CN103429581B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280011690.XA CN103429581B (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2012100082869 2012-01-12
CN201210008286.9 2012-01-12
CN201210008286 2012-01-12
PCT/CN2012/087606 WO2013104257A1 (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用
CN201280011690.XA CN103429581B (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN103429581A CN103429581A (zh) 2013-12-04
CN103429581B true CN103429581B (zh) 2015-08-26

Family

ID=48781054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280011690.XA Active CN103429581B (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Country Status (14)

Country Link
US (1) US9139548B2 (https=)
EP (1) EP2803664B1 (https=)
JP (1) JP6122871B2 (https=)
KR (1) KR102036547B1 (https=)
CN (1) CN103429581B (https=)
AU (1) AU2012365706B2 (https=)
BR (1) BR112014016648B1 (https=)
CA (1) CA2860353A1 (https=)
MX (1) MX357780B (https=)
RU (1) RU2621039C1 (https=)
TW (1) TWI588136B (https=)
UA (1) UA115975C2 (https=)
WO (1) WO2013104257A1 (https=)
ZA (1) ZA201404625B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
WO2022053013A1 (zh) * 2020-09-10 2022-03-17 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015062486A1 (en) * 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104788412B (zh) * 2014-01-22 2017-02-15 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
JP2017533981A (ja) 2014-10-14 2017-11-16 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 香料としてのヘキサデカ−８，１５−ジエナールの使用
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
CN108236609B (zh) * 2016-12-27 2022-10-21 江苏恒瑞医药股份有限公司 一种gpr40激动剂药物组合物及其制备方法
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630152A1 (en) * 2003-05-30 2006-03-01 Takeda Pharmaceutical Company Limited Condensed ring compound
US20070244155A1 (en) * 2006-03-14 2007-10-18 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CN101616913A (zh) * 2006-06-27 2009-12-30 武田药品工业株式会社 稠环化合物
WO2010123016A1 (ja) * 2009-04-22 2010-10-28 アステラス製薬株式会社 カルボン酸化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100381584B1 (ko) * 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
NZ592603A (en) 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
SG173027A1 (en) 2009-01-30 2011-08-29 Toyama Chemical Co Ltd N-acyl anthranilic acid derivative or salt thereof
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630152A1 (en) * 2003-05-30 2006-03-01 Takeda Pharmaceutical Company Limited Condensed ring compound
US20070244155A1 (en) * 2006-03-14 2007-10-18 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CN101616913A (zh) * 2006-06-27 2009-12-30 武田药品工业株式会社 稠环化合物
WO2010123016A1 (ja) * 2009-04-22 2010-10-28 アステラス製薬株式会社 カルボン酸化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
WO2022053013A1 (zh) * 2020-09-10 2022-03-17 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Also Published As

Publication number Publication date
KR20140117498A (ko) 2014-10-07
CA2860353A1 (en) 2013-07-18
CN103429581A (zh) 2013-12-04
MX357780B (es) 2018-07-24
BR112014016648A8 (pt) 2017-07-04
AU2012365706B2 (en) 2015-08-20
HK1188781A1 (zh) 2014-05-16
EP2803664B1 (en) 2018-11-21
AU2012365706A1 (en) 2014-07-24
UA115975C2 (uk) 2018-01-25
EP2803664A4 (en) 2015-10-28
JP2015503595A (ja) 2015-02-02
US9139548B2 (en) 2015-09-22
TWI588136B (zh) 2017-06-21
WO2013104257A1 (zh) 2013-07-18
US20150005282A1 (en) 2015-01-01
TW201329058A (zh) 2013-07-16
KR102036547B1 (ko) 2019-10-25
RU2621039C1 (ru) 2017-05-31
JP6122871B2 (ja) 2017-04-26
ZA201404625B (en) 2015-11-25
MX2014008125A (es) 2014-09-22
BR112014016648B1 (pt) 2020-10-27
EP2803664A1 (en) 2014-11-19
BR112014016648A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CN103429581B (zh) 多环类衍生物、其制备方法及其在医药上的应用
TWI617546B (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
BR112021014180A2 (pt) Composto, medicamento, método para ativar um receptor de orexina tipo 2 em um mamífero, método para profilaxia ou tratamento de narcolepsia em um mamífero, e, uso de um composto
WO2020238791A1 (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
BRPI0924126B1 (pt) Composto heterocíclico bicíclico, medicamento, inibidor de sns, composição farmacêutica e uso do referido composto
TWI701251B (zh) 吡唑并[1,5-a][1,3,5]三-2-胺類衍生物、其製備方法及其在醫藥上的應用
TW201514136A (zh) 組蛋白去乙醯酶抑制劑及組成物，暨其使用之方法
WO2008069242A1 (ja) 新規２環性複素環化合物
WO2004091605A1 (ja) アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤
WO2020169042A1 (zh) 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
JP6231621B2 (ja) 新規ベンゾアゼピン誘導体及びその医薬用途
KR20260035948A (ko) 개질된 플라보노이드계 화합물 및 그 응용
KR101615114B1 (ko) 신규한 벤조티오펜 옥시드 유도체 또는 그의 염
TW202416988A (zh) 含氮雜環的多環化合物的游離鹼晶型及其製備方法
CN116438177A (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
CN107428682A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TW202114989A (zh) 吡啶苯甲醯胺類衍生物、其製備方法及其在醫藥上的應用
HK1188781B (en) Polycyclic derivatives, preparation method and medical uses thereof
RU2845145C1 (ru) Соединения для подавления рака с мутацией egfr и их фармацевтическое применение
TWI643847B (zh) Novel benzoazepine derivatives and their medical uses
WO2024251133A1 (zh) 作为α5-GABAA受体调节剂的杂环化合物及其用途
HK40061204B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
BR112021001853A2 (pt) derivado de benzeno
HK1240210A1 (en) Amide derivative, and preparation method and pharmaceutical use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188781

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1188781

Country of ref document: HK